コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ls during the development and progression of atherosclerotic disease.
2 oninvasively image experimental and clinical atherosclerotic disease.
3 for endovascular treatment of aneurysmal and atherosclerotic disease.
4 fication of asymptomatic subjects at risk of atherosclerotic disease.
5 as an attractive target for the treatment of atherosclerotic disease.
6 nction represents the first manifestation of atherosclerotic disease.
7 al thrombosis but also in the progression of atherosclerotic disease.
8 l utility in the prophylaxis of inflammatory atherosclerotic disease.
9 a source of bypass conduit for patients with atherosclerotic disease.
10 ciation studies for their relevance in human atherosclerotic disease.
11 m failed to induce regression of established atherosclerotic disease.
12 rrent microbial infections may contribute to atherosclerotic disease.
13 st commonly be the result of degenerative or atherosclerotic disease.
14 revascularization in the setting of diffuse atherosclerotic disease.
15 Noninvasive imaging can detect early atherosclerotic disease.
16 -cell responses influence the progression of atherosclerotic disease.
17 ant therapeutic targets in the management of atherosclerotic disease.
18 and either prevent or reverse the course of atherosclerotic disease.
19 idence that chronic inflammation may promote atherosclerotic disease.
20 hat infection does play an important role in atherosclerotic disease.
21 ithin the arterial wall and are a prelude to atherosclerotic disease.
22 ere considered representative of significant atherosclerotic disease.
23 DL are commonly encountered in patients with atherosclerotic disease.
24 evention of coronary heart disease and other atherosclerotic disease.
25 c disease and in the progression of coronary atherosclerotic disease.
26 portant mechanisms by which smoking promotes atherosclerotic disease.
27 cal setting for the investigation of carotid atherosclerotic disease.
28 idely used to treat hypercholesterolemia and atherosclerotic disease.
29 ugments conventional mechanical treatment of atherosclerotic disease.
30 blood lipid levels, a known risk factor for atherosclerotic disease.
31 nd reproducible noninvasive marker of global atherosclerotic disease.
32 e for symptomatic patients with intracranial atherosclerotic disease.
33 he genesis and progression of human coronary atherosclerotic disease.
34 pproaches to the treatment and prevention of atherosclerotic disease.
35 factors is the major strategy for preventing atherosclerotic disease.
36 ns between bacterial or viral infections and atherosclerotic disease.
37 s commonly associated with predisposition to atherosclerotic disease.
38 ns and increased risk of clinically manifest atherosclerotic disease.
39 acute coronary syndromes and progression of atherosclerotic disease.
40 centration of LDL is a major risk factor for atherosclerotic disease.
41 and should greatly enhance basic studies of atherosclerotic disease.
42 macrophage function with relevance for human atherosclerotic disease.
43 mited assessment of changes in the extent of atherosclerotic disease.
44 on lipids may impact the risk of developing atherosclerotic disease.
45 ls have been associated with the presence of atherosclerotic disease.
46 le risk factors associated with intracranial atherosclerotic disease.
47 tic patients have more extensive and diffuse atherosclerotic disease.
48 esting that they may represent less advanced atherosclerotic disease.
49 sGC inhibition may provide a novel target in atherosclerotic disease.
50 ychosocial factors in the pathophysiology of atherosclerotic disease.
51 ately benefit individuals with more advanced atherosclerotic disease.
52 ng adults 60 years or older without clinical atherosclerotic disease.
53 -enhanced BB 3-T MR imaging for intracranial atherosclerotic disease.
54 investigation, especially in the context of atherosclerotic disease.
55 n murine models of vascular injury and human atherosclerotic disease.
56 es mellitus is prospectively associated with atherosclerotic disease.
57 temic inflammation, and an increased risk of atherosclerotic disease.
58 stically demonstrates inflammatory damage in atherosclerotic disease.
59 new therapeutic strategies in CKD-associated atherosclerotic disease.
60 eatly benefit the detection and treatment of atherosclerotic disease.
61 were examined for the presence of neointimal atherosclerotic disease.
62 tified, principally in cases with concurrent atherosclerotic disease.
63 ns are critical given the systemic nature of atherosclerotic disease.
64 for ischemic events resulting from coronary atherosclerotic disease.
65 nts with high-grade symptomatic intracranial atherosclerotic disease.
66 y and prevent the clinical manifestations of atherosclerotic disease.
67 population and in those with already present atherosclerotic disease.
68 ls are inversely related to the incidence of atherosclerotic disease.
69 suggested a contribution of periodontitis in atherosclerotic diseases.
70 age of drugs and diets to reduce the risk of atherosclerotic diseases.
71 y heart disease and cerebrovascular or other atherosclerotic diseases.
72 al effects of new drugs aiming to cure human atherosclerotic diseases.
73 attractive therapeutic strategy in occlusive atherosclerotic diseases.
77 is associated with clinical and subclinical atherosclerotic disease, although evidence from prospect
78 mbar radiograms, are a marker of subclinical atherosclerotic disease and an independent predictor of
80 c and mechanical approaches to patients with atherosclerotic disease and have resulted in improved cl
82 ensity lipoprotein in the protection against atherosclerotic disease and in the progression of corona
83 nosis,regardless of symptoms, is a marker of atherosclerotic disease and increased risk for cardiovas
84 In the majority of patients with clinical atherosclerotic disease and isolated hypoalphalipoprotei
85 iplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than
88 rdiovascular concerns, including the risk of atherosclerotic disease and systemic inflammation, in ex
89 r accounting for an indicator of subclinical atherosclerotic disease and traditional risk factors and
90 er FKN is expressed throughout all stages of atherosclerotic disease and whether it directly contribu
91 erved in patients with CKD but without overt atherosclerotic disease and with few traditional risk fa
92 tions are associated with increasing risk of atherosclerotic disease and with graft stenosis and occl
93 angioplasty, or PTCA) patients with advanced atherosclerotic disease and with procedures performed ac
94 s the relationship between PON1 activity and atherosclerotic diseases and various factors modulating
96 demia, extracranial carotid and intracranial atherosclerotic disease, and antithrombotic therapy.
97 actors, progression, coprevalence with other atherosclerotic disease, and association with incident c
98 seases, including allergic rhinitis, sepsis, atherosclerotic disease, and malignancy, in which PAF si
100 a significant approximately 70% decrease in atherosclerotic disease area in double knockout mice on
101 on, would likely lead to the displacement of atherosclerotic disease as the nation's number 1 killer.
102 ated blood lipids and diabetes contribute to atherosclerotic disease, as well as to understand the mo
103 but who did not have either cancer or known atherosclerotic disease at the time of imaging were incl
105 loci and identify candidate genes for human atherosclerotic disease based on circular chromosome con
106 tid arteries and in differentiating TAK from atherosclerotic disease based on minimal plaque content,
108 onary events mandates a greater focus on the atherosclerotic disease burden rather than on features o
111 ith hyperlipidemia, hypercholesterolemia and atherosclerotic diseases by reducing cholesterol level a
113 he developing atheroma and may contribute to atherosclerotic disease development and progression.
120 Understanding how symptomatic intracranial atherosclerotic disease (ICAD) evolves with current medi
121 MR) imaging protocol to measure intracranial atherosclerotic disease (ICAD) in a population-based mul
123 eptibility loci for their underlying disease-atherosclerotic disease-identification of candidate gene
124 rable lipid profiles and reduced subclinical atherosclerotic disease in a Pennsylvania Amish populati
125 ioImage Study (A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population) sought
126 d cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies.
127 c nitrate might prove useful in ameliorating atherosclerotic disease in Apolipoprotein (Apo)E knockou
128 tructure, detect the presence of subclinical atherosclerotic disease in high-risk patient subgroups,
129 tly required for the development of advanced atherosclerotic disease in mice with a severe defect in
133 ound images were examined from patients with atherosclerotic disease in the proximal left anterior de
138 gs reveal that lipid changes associated with atherosclerotic disease induce decreased production of I
139 s by which cytomegalovirus may contribute to atherosclerotic disease initiation and progression and t
141 data suggest evolocumab use in patients with atherosclerotic disease is efficacious and safe in patie
143 ns with chronic kidney disease (CKD) because atherosclerotic disease is less prevalent, whereas bleed
145 diac events among young individuals, whereas atherosclerotic disease is primarily responsible for the
146 at endovascular stenting of vertebral artery atherosclerotic disease is safe and effective compared w
148 nterventional and pharmacological therapy of atherosclerotic disease, it is still the leading cause o
149 to reduce the severity of stenotic coronary atherosclerotic disease, its long-term success is signif
150 s is a well-recognized phenomenon in chronic atherosclerotic disease, its role in sudden coronary dea
151 that changes in lipid profiles that reflect atherosclerotic disease led to activation of skin murine
153 od flow (pCBF) in 575 patients with manifest atherosclerotic disease (mean age, 57 +/- 10 years) from
154 33 years +/- 4 [SD]) and five patients with atherosclerotic disease (mean age, 67 years +/- 11.7).
155 th primary prevention of clinically manifest atherosclerotic disease, must begin in childhood or adol
157 and selected based on the presence of known atherosclerotic disease (non-HIV atherosclerotic control
158 Framingham risk score (FRS) and had no known atherosclerotic disease (non-HIV FRS-matched controls).
160 ho are known to have coronary heart disease, atherosclerotic disease of the aorta or peripheral arter
161 patients with known or clinically suspected atherosclerotic disease of the aortic arch and branch ve
162 logic and clinical natural history of severe atherosclerotic disease of the thoracic aorta as defined
164 g ATP and ADP are especially associated with atherosclerotic diseases of younger age and smoking.
166 cumab versus placebo in 27 564 patients with atherosclerotic disease on statin therapy followed for a
167 fter intervention may be a marker of diffuse atherosclerotic disease or a consequence of catheter-bas
169 In asymptomatic AS patients without known atherosclerotic disease or diabetes mellitus, ELI provid
172 of high-risk patients with manifestations of atherosclerotic disease or who have a coronary artery di
173 iring interaction with other risk factors or atherosclerotic disease, or may result from disease rath
174 se drives the neovascularization observed in atherosclerotic disease, our findings identify a possibl
175 n for patients with symptomatic intracranial atherosclerotic disease, particularly those with high-gr
176 as and volumes that occur as a result of the atherosclerotic disease process and during transcatheter
179 elial dysfunction are common features of the atherosclerotic disease process, this unique dual-domain
181 There is evidence that early detection of atherosclerotic disease processes and subsequent therape
183 eagents for rapid and noninvasive imaging of atherosclerotic disease progression and plaque vulnerabi
186 n has been cross-sectionally associated with atherosclerotic disease risk factors, but the prospectiv
187 sessed echocardiographic characteristics and atherosclerotic disease risk in 201 survivors of childho
192 atients with diabetes are at higher risk for atherosclerotic disease than nondiabetic individuals wit
193 for 37 disease susceptibility loci for human atherosclerotic disease that are of potential interest t
194 in many high-risk patients with established atherosclerotic disease, the elevations in HDL achieved
196 inate artery revascularization for occlusive atherosclerotic disease to relieve neurologic (n = 85) a
197 Patients with symptomatic femoro-popliteal atherosclerotic disease undergoing percutaneous translum
198 ts undergo routine screening for subclinical atherosclerotic disease using myocardial perfusion scint
199 LAQUE (Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimo
200 d to men and women, aged 60-69 years, in the Atherosclerotic Disease VAscular functioN and genetiC Ep
201 morphisms (SNPs) in the risk interval in the Atherosclerotic Disease, Vascular Function, and Genetic
202 n some of the decline in angina and coronary atherosclerotic disease visits, it seems that other fact
204 men and 4968 women with no prior history of atherosclerotic disease who had baseline Lp(a) determina
205 onth) versus placebo in 27 564 patients with atherosclerotic disease who were on statin therapy, foll
206 us placebo in patients with, or at risk for, atherosclerotic disease who were undergoing noncardiac s
207 heart disease who are found to have coronary atherosclerotic disease with <50% diameter stenosis may
208 on outcome for muscle ischemia due to severe atherosclerotic disease, with an overall incidence of 10
209 receiving OAC+ASA did not have a history of atherosclerotic disease, yet 17% had elevated Anticoagul
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。